Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

TPEX:7871 Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	681.88	88.12	30.53
Cash & Short-Term Investments	681.88	88.12	30.53
Cash Growth	-	188.60%	-
Accounts Receivable	2.35	2.4	1.43
Other Receivables	8.68	7.53	0.26
Receivables	11.02	9.92	1.69
Prepaid Expenses	1.95	1.25	0.79
Other Current Assets	-	0.2	0.01
Total Current Assets	694.86	99.49	33.03
Property, Plant & Equipment	23.3	26.69	22.78
Long-Term Investments	-	-	0.29
Other Intangible Assets	16.68	12.59	14.4
Other Long-Term Assets	10.42	9.86	10.01
Total Assets	745.25	148.63	80.51
Accrued Expenses	14.37	18.6	51.13
Short-Term Debt	-	1,345	731.92
Current Portion of Long-Term Debt	6.5	6.5	6.5
Current Portion of Leases	4.22	4.16	4.91
Current Income Taxes Payable	3.52	3.93	3.68
Other Current Liabilities	5.85	13.19	13.86
Total Current Liabilities	34.46	1,392	812
Long-Term Debt	8.67	11.92	18.42
Long-Term Leases	10.9	13.02	16.61
Total Liabilities	54.03	1,417	847.02
Common Stock	3.81	0.7	0.69
Additional Paid-In Capital	2,802	15.24	11.9
Retained Earnings	-2,225	-1,205	-764.54
Comprehensive Income & Other	110.56	-78.97	-14.56
Shareholders' Equity	691.23	-1,268	-766.51
Total Liabilities & Equity	745.25	148.63	80.51
Total Debt	30.28	1,381	778.35
Net Cash (Debt)	651.6	-1,293	-747.82
Net Cash Per Share	27.44	-58.42	-9.36
Filing Date Shares Outstanding	128.6	22.41	21.86
Total Common Shares Outstanding	128.6	22.41	21.86
Working Capital	660.4	-1,292	-778.97
Book Value Per Share	5.38	-56.57	-35.07
Tangible Book Value	674.55	-1,280	-780.92
Tangible Book Value Per Share	5.25	-57.13	-35.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.